|
24 Residents Dead in 3 Weeks as One Third of UK Nursing Home Residents Die After Experimental mRNA COVID Injectionsby Brian Shilhavy Editor, Health Impact News In what is becoming almost a daily report of massive nursing home deaths following injections of experimental mRNA COVID shots, a nursing home in the U.K. is reporting over one third of their residents have died after receiving the mRNA experimental COVID injections. We are now seeing a very predictable pattern as we are reporting all over the world where the elderly are dying at a very alarming rate following mass vaccinations of the experimental mRNA injections. And in all of these cases, the local media is quoting local officials as saying that the “vaccines” have nothing to do with the deaths. They are also stating that deaths following the experimental mRNA injections are “expected.” How can people keep believing this is true? This is now happening all over the world, in many locations, and we are just supposed to accept by faith that COVID outbreaks happened simultaneously with the mass vaccinations, but that there is no connection to the injections? Here is what the Daily Echo is reporting about the nursing home deaths in Basingstoke in the UK: At least twenty-two people have died at a Hampshire care home (Daily Mail is reporting 24 deaths) in one of the worst known outbreaks of the coronavirus pandemic to date. The deaths occurred at Pemberley House Care Home in Basingstoke, operated by private firm Avery Healthcare. The outbreak was first declared on Tuesday, January 5, with 60 per cent of its residents testing positive for the disease, according to sources. Within three weeks, 22 people had died – over one-third of the home’s residents. It is understood the outbreak started as residents began to have their first coronavirus vaccines. The Medicines and Healthcare Products Regulation Agency (MHRA) said there was no suggestion the vaccine was responsible for the deaths. Government advice states that one “can not catch Covid-19 from the vaccine but it is possible to have caught Covid-19 and not realise you have the symptoms until after your vaccination appointment”, adding that it may take “a week or two” after the first dose to build up protection. A spokesperson for the MHRA said they were saddened by the deaths but said they were not linked to the vaccine patients might have received, saying: “We are saddened to hear about any deaths which have occurred since receiving COVID-19 vaccination. However, our surveillance does not suggest that the COVID-19 vaccines have contributed to any deaths. It is not unexpected that some of these people may naturally fall ill due to their age or underlying conditions shortly after being vaccinated, without the vaccine playing any role in that.” Full Article. However, many healthcare workers who work in these assisted living centers are now challenging this narrative, that these deaths are due to “natural illnesses” among the elderly that have nothing to do with the shots, including a whistleblower who is a Certified Nursing Assistant and went public with what he was seeing in his nursing home. He reported that: after being injected with the mRNA shot, residents who used to walk on their own can no longer walk. Residents who used to carry on an intelligent conversation with him could no longer talk. And now they are dying. “They’re dropping like flies.” (Full article with video.) The basic premise being used to justify saying that none of these deaths are linked to the experimental COVID injections is that “one can not catch Covid-19 from the vaccine,” which is the position of the FDA as well. From the Daily Echo: Government advice states that one “can not catch Covid-19 from the vaccine but it is possible to have caught Covid-19 and not realise you have the symptoms until after your vaccination appointment”, adding that it may take “a week or two” after the first dose to build up protection. From the FDA: WILL THE MODERNA COVID-19 VACCINE GIVE ME COVID-19? No. The Moderna COVID-19 Vaccine does not contain SARS-CoV-2 and cannot give you COVID-19. Therefore, the reasoning continues, if these residents who died are all tested as positive for COVID-19, then, according to “Government sources,” they could not have died from the vaccines. Do you see how this whole argument falls apart if the premise that the “vaccine” cannot give someone COVID-19 turns out to actually be false? And the evidence so far points to the fact that this belief about a new product that has only been in the market for a few weeks and was fast-tracked to get it into the market, and supposedly cannot give someone COVID-19, is not true. The largest mass injection campaign that has happened so far has occurred in Israel, and their data shows that over 12,000 people became infected with COVID-19 AFTER the injections. See: 12,400 People in Israel Tested Positive for Coronavirus AFTER Being Injected with the Experimental Pfizer COVID Shot The correlations between the roll outs of these experimental mRNA injections and nursing home deaths is very clear. The Daily Mail, while reporting on the tragedy at the Pemberley House Care Home in Basingstoke, also reported that similar rates of deaths are being seen throughout the UK in “care homes,” which they are blaming on the COVID virus. They produced this chart: The UK’s national statistics body found 1,705 care home residents died from the virus in the week ending January 22, up from 661 a fortnight ago. Source. And while the government keeps blaming these deaths on the virus, what else happened in December when numbers of deaths were actually on the decline, until rapidly spiking upwards in January? The roll out of the Pfizer, and later Moderna, experimental mRNA COVID injections began in December. It is time to challenge the “official” position that because these injections do not contain a COVID19 virus, they cannot give someone the virus, because something is clearly causing these people who are dying “from COVID” to test positive. Perhaps we should have a better understanding of just how these mRNA injections work. Dr. Lee Merritt, MD, recently was interviewed by Alex Newman of The New America. Dr. Lee Merritt began her medical career at the age of four, carrying her father’s “black bag” on housecalls, along the back roads of Iowa. In 1980 she graduated from the University of Rochester School of Medicine and Dentistry in New York, where she was elected to life membership in the Alpha Omega Alpha Honor Medical Society. Dr. Merritt completed an Orthopaedic Surgery Residency in the United States Navy and served 9 years as a Navy physician and surgeon where she also studied bioweapons before returning to Rochester, where she was the only woman to be appointed as the Louis A. Goldstein Fellow of Spinal Surgery. Dr. Merritt has been in the private practice of Orthopaedic and Spinal Surgery since 1995, has served on the Board of the Arizona Medical Association, and is past president of the Association of American Physicians and Surgeons. (Source.) We have copied the section of her interview with Alex Newman where she discusses the mRNA “vaccines.” This is from our Bitchute Channel (it is also available on Rumble): A partial transcript: Well I have lots of concerns. Not the least of which is for the integrity and the moral turpitude of the medical profession. If you look at the history of these vaccines, just real quickly, these are experimental biologics. I don’t even like to call them “vaccines,” because classically how a vaccine works is this: You grow a bunch of the pathogens, so let’s say its measles. You grow the measles in a vat or in eggs, and then you take a portion of that, and you make it less strong. You attenuate it. You make it weaker, and there are different ways of doing that, and then you inject it into people, and their own immune system sees that weakened pathogen. And then they react to it just enough that it puts it in their immulogic memory. And then when they’re exposed to it the next time, they memorize it and theoretically they can better respond. That’s what your real body does when it gets sick. Without all this vaccination stuff, you get sick with a virus, you get perfect life-long immunity, for the most part, and it’s over. So how is this (mRNA injections) different? Well, they’re not giving you a pathogen, or a piece of a pathogen, or a small piece with an adjuvant. What they’re doing is programming mRNA. And mRNA has a little piece of, it’s like DNA, but it’s the messenger RNA. It’s what makes proteins in the body. It’s kind of like a computer chip that you put into a 3D printer and then you tell it what you want it to make, and it prints it out. We have that in engineering, and this is the biological equivalent. I make some mRNA, and it tells your body to do certain things. Well, in this case what they’ve done, they’ve made a piece of this mRNA to create in every cell in your body that spike protein. Or at least part of it. And that spike protein, you’re actually creating the pathogen in your body. This is where it gets a little wishy about how much of that spike protein is actually being created, and I don’t know how to find that out, I can’t find that, but I’m sure somebody knows. What happens is, and this is the problem. I’ll tell you what happened in the animal studies. There’s been four different vaccines and three different animal studies that I know about. They started after SARS, and they did cats. And then after that MERS, which were all coronavirus pathogens that are more deadly (then COVID-19), and after MERS they tried it in ferrets. So what happened was all animals died. Let me just point out. We have never made it through an animal study successfully for this type of virus. We have never done this in humans before. At least we haven’t. Maybe the Chinese have. We don’t really have a track record of success. This vaccine was rolled out to distribution centers before they even made a show of caring about the FDA approving it. Do you realize that? I’ve never seen that happen before. And the longest they’ve really followed people after the vaccine is two months. That’s not enough time to know we won’t have that antibody enhancement problem. On potential for military use: I will make this military point. This is a perfect binary weapon. There’s no way I know exactly what that mRNA is programmed to do, and neither do you and neither do most doctors. The doctors can’t get at that data. The guys at the very top of this project, they know. But we don’t know. So, do you still trust your government saying that these mRNA injections cannot cause someone to get COVID? Or do the facts speak for themselves? Because the data, the REAL facts, show that seniors are dying very suddenly just after the mRNA vaccination programs are started in these assisted living centers. Who are the “guys at the top” of “this project” that truly know what these mRNA injections are programmed to do whom Dr. Merritt referred to? xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx CORONAVIRUS: A Globalist Bioweapon Created by DARPA, Big Pharma, Bill Gates and his British Overlords Posted on January 28, 2020 by State of the Nation FacebookTwitterPinterestRedditEmailShare Definitive proof that Coronavirus is a globalist bioweapon Patriots for Truth https://tinyurl.com/ujs4m34 Proof the Coronavirus is a bioweapon created by DARPA, Bill Gates, Defra,* Wellcome Trust (UK), and European Commission (EU) * UK Department for Environment, Food and Rural Affairs The CORONAVIRUS patent (from the UK) was approved in 17 months by SERCO (UK) that runs the U.S. Patent Office CORONAVIRUS was funded and patented by Wellcome Trust (UK, fake sold to GlaxoSmithKline), Bill & Melinda Gates Foundation, DARPA, DEFRA (UK), World Health Organization, European Commission (EU) via THE PINBRIGHT INSTUTUTE (UK) coronavirus 2 U.S. Pat. No. 10,130,701. (Nov. 20, 2018). CORONAVIRUS. Assignee: THE PIRBRIGHT INSTITUTE (Woking, Pirbright, Great Britain), funded by Wellcome Trust, Bill & Melinda Gates Foundation, EU. U.S. Patent Office. https://www.fbcoverup.com/docs/library/2018-11-20-US-Pat- No-10130701-CORONAVIRUS-Assignee-THE-PIRBRIGHT-INSTUTUTE- Woking-Great-Britain-funded-by-Wellcome-Trust-and-Gates-Foundation-USPTO-Nov-20-2018.pdf From the USPTO patent application “wrapper” files accessible by the public in PUBLIC PAIR. https://portal.uspto.gov/pair/PublicPair coronavirus 4 The Coronavirus patent was issued in just 17 months from initial filing—that’s almost unheard of speed—with very little objection from back from SERCO (UK)-managed patent examiner Bao Q. Li coronavirus 4 List of patents assigned to THE PIRBRIGHT INSTITUTE (funded by Wellcome Trust, Bill & Melinda Gates Foundation, EU & DARPA) The Pirbright Institute (Woking GB). (Compiled Jan. 28, 2020). Coronavirus et al Patent Assignee for Pat. Nos. 10,507,237; 10,294,277; 10,202,578; 10,130,701; 9,969,777; 9,457,075; 9,243,230; 9,145,548; 8,828,407; 8,501,466; 8,455,201. U.S. Patent Office. https://www.fbcoverup.com/docs/library/2020-01-28- The-Pinbright-Institute-Woking-GB-Coronavirus-et-al- Patents-Assigned-to-AN_Pinbright-compiled-Jan-28-2020.pdf CEO: Professor Bryan Charleston https://www.pirbright.ac.uk/users/prof-bryan-charleston pirbrightcoronavirus 5vaccine bryan charlestonPirbright 2partnerspirbright 3 For our regular readers, remember that Burroughs Wellcome & Co. bankrolled the First Imperial Press Conference, 1909 and Empire Press Union with British MI6, MI5 and GC&CS (renamed GCHQ in 1946) formed a month later. Burroughs Wellcome & Co. supplied medical kits full of experimental vaccines to the British 2nd Boer War that killed over 60,000 blacks and whites in the world’s first modern concentration camp vaccine experiments. See AFI. (Oct. 24, 2019). The 200-year Information War: The UK-U.S. Pilgrims Society controls the Press that directs intelligence (spy-lies) to bend words and culture to atheistic social fascism. Americans for Innovation. alfred milner https://americans4innovation.blogspot.com/ 2019/10/the-200-year-information- war-uk-us.html Get these facts to every decision influencer in your community. And, pray for these lost souls and the souls of their innocent victims. Note: A joint investigation by Americans for Innovation and American Intelligence Media contributors not be relied upon without independent verification. Think for yourself. Fair Use is relied upon for all content. No claims are made to the properties of third parties. For educational purposes only. ___ https://patriots4truth.org/2020/01/28/corona-virus-is-a- globalist-bioweapon/ xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx MODERNAgate: Bill Gates Busted, Queen Implicated & Wellcome Trust IncriminatedPosted on August 6, 2020 by State of the NationFacebookTwitterPinterestRedditEmailShareMODERNA’S TOTALLY DISQUALIFYING RED FLAG “STRATEGIC” RELATIONSHIPS TO THE QUEEN, WELLCOME TRUST, AND BILL GATES Americans for Innovation Aim4Truth.org Readers: This is a work in progress. Please check back in another day to see what else we have found out about this INSIDER TRADING group. We will be adding material as it comes in from the mines. Mike and Doug explain what this disclosure means in our war with the ‘Invisible Enemy’. Insider trading thumbnail RAW AUDIO FILE: HTTPS://AIM4TRUTH.ORG/WP-CONTENT/ UPLOADS/2020/08/MASSIVE-INSIDER-TRADING-AT-MODERNA-INC.-.MP3 MODERNA INC (MRNA) STOCK FRAUD Bill Gates, AztraZeneca (the British Crown, Rothschild), Goldman Sachs, J.P. Morgan (Rothschild), Morgan Stanley. Barclays (Rothschild), Bank of America, Vertex Pharmaceuticals (Rothschild), Merck, DARPA (the U.S. Defense Department!) ALL MUST BE DISQUALIFIED AND DISMISSED FROM INVOLVEMENT WITH CORONAVIRUS treatment recommendations involving Moderna, or Moderna associated INTERLOCKING RELATIONSHIPS that are both monopolistic and seditious. Moderna, Inc., CIK# 0001682852. (Filed Dec. 04, 2018). Form S-1/A Initial Public Offering. SEC Edgar. https://www.fbcoverup.com/docs/library/ 2018-12-04-Moderna-Inc-MRNA-CIK-0001682852-S-1A-Initial- Public-Offering-SEC-Edgar-Filed-Dec-04-2018.pdf Also, https://www.sec.gov/Archives/edgar/data/1682852/000119312518341958/d611137ds1a.htm platform (About 100 patents have been issued in the U.S. Moderna does not disclose the numbers in their S-1/A.) patent search . MODERNA (NASDAQ: MRNA) INSIDER TRADING REPORTS (FORM 4) CEO Stephan Bancel Key officers and directors: Sell, Sell, Sell! https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852 (Note to readers: We will have this chart formatted in a better way shortly.) Owner Filings Transaction Date Type of Owner Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer Zaks Tal Zvi 0001690927 2020-07-27 officer: Chief Medical Officer Hoge Stephen 0001760669 2020-07-23 officer: President NABEL ELIZABETH G 0001619929 2020-07-15 director Tallett Elizabeth E 0001192460 2020-07-01 director HENDERSON LORI M. 0001221127 2020-06-18 officer: General Counsel and Secretary Meline David W 0001444612 2020-06-08 officer: Chief Financial Officer Kim Lorence H. 0001643746 2020-06-02 officer: Chief Financial Officer AFEYAN NOUBAR 0001222012 2020-05-21 director, 10 percent owner Flagship Ventures Fund IV, L.P. 0001503559 2020-05-21 10 percent owner Flagship Ventures Fund IV General Partner LLC 0001508051 2020-05-21 director, 10 percent owner Flagship Ventures Fund IV-Rx, L.P. 0001590973 2020-05-21 10 percent owner Andres Juan 0001760670 2020-05-13 officer: See remarks SAGAN PAUL 0001035440 2020-04-29 director LANGER ROBERT 0001239757 2020-04-29 director Nader Francois 0001365343 2020-04-29 director Horning Sandra 0001638709 2020-04-29 director Slaoui Moncef 0001712369 2020-04-29 director Berenson Stephen 0001760671 2020-04-29 director LEE JENNIFER LING 0001675118 2020-03-09 officer: Chief Accounting Officer moderna-mrna-stock-chart-accessed-am-aug-04-2020 Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer https://www.fbcoverup.com/docs/library/ 2020-07-29-Moderna-Stephane-Bancel-CEO- Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf stephane bancel Sold $30,840,614 in shares in his name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally. https://www.crunchbase.com/organization/bb-biotech-ventures A Zurich, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG. http://www.bbbiotechventures.com/en/bb-biotech-ventures/ Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard, . . . . . . . FYI. Ole Stevie boy has been selling his stock out since Nov. 2019. NO BUYS. ALL SELLS. https://www.fbcoverup.com/docs/library/ 2020-08-03-Stephane-Bancel-CEO-Moderna-Inc-Form-D-Insider- Trading-Report-SEC-accessed-Aug-03-2020.pdf bancel stephane https://yuzuha.substack.com/p/interview-with-moderna-ceo-stephane . . . . . . . Moderna’s latest Proxy Statement Form DEF 14A dated Apr. 10, 2020 MASSIVE WELLCOME TRUST CONFLICT OF INTEREST Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline – GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware, Moderna’s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust – co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO’S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https://heightzone.com/dr-tal-zaks/ Israeli Tal Zaks – Been only selling his Moderna stock (dumping) since Dec. 2019 This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine. That is illegal stock manipulation and should land him and his CEO in jail. C’mon Bill Barr, do your job. stephane bancel 2 Moderna’s Israeli Chief Medical Officer Tal Zaks has been dumping his stock since December 2019, just one month after CEO Stephane Bancel starting dumping his. Where is the SEC, Bill Barr, the underwriters? The US stock market IPO system is totally rigged for the Pilgrims Society in Britain and America. https://www.sec.gov/Archives/edgar/data/1682852/ 000119312520103908/d915867ddefa14a.htm Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings) IRS No.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231 Type: DEFA14A | Act: 34 | File No.: 001-38753 | Film No.: 20787049 SIC: 2836 Biological Products, (No Diagnostic Substances) Office of Life Sciences MANAGEMENT Executives, non-executive directors and director nominee The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020. https://www.sec.gov/Archives/edgar/data/ 1682852/000119312520103908/d915867ddefa14a.htm MANAGEMENT See Resumes: At the bottom of this post. Executives, non-executive directors and director nominee The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020. Name Age Position Executives: Stéphane Bancel (1) 47 Chief Executive Officer and Director Juan Andres (1) 55 Chief Technical Operations and Quality Officer Marcello Damiani 50 Chief Digital and Operational Excellence Officer Tracey Franklin 40 Chief Human Resources Officer Lori Henderson, J.D. (1) 58 General Counsel and Corporate Secretary Stephen Hoge, M.D. (1) 44 President Lorence Kim, M.D. (1) 45 Chief Financial Officer Tal Zaks, M.D., Ph.D. (1) 54 Chief Medical Officer Non-Executive Directors: Noubar B. Afeyan, Ph.D. (4)(5) 57 Chairman, Director Stephen Berenson (2)(3) 59 Director Robert Langer, Sc.D. (4) 71 Director Elizabeth Nabel, M.D. (4)(5) 68 Director François Nader, M.D.(5) 63 Director Israel Ruiz(2)(3) 48 Director Paul Sagan (2)(3) 61 Director Moncef Slaoui, Ph.D.(5) 60 Director Director Nominee: Sandra Horning, M.D. 71 Director nominee -1 Executive officer -2 Member of the Audit Committee -3 Member of the Compensation and Talent Committee -4 Member of the Nominating and Corporate Governance Committee -5 Member of the Product Development Committee See the resumes of the above-mentioned people at the bottom of this post. These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING relationships from any involvement in Coronavirus. https://www.sec.gov/Archives/edgar/data/ 1682852/000119312518341958/d611137ds1a.htm moderna edgar search . moderna registration “Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck & Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill & Melinda Gates Foundation. As of September 30, 2018, we have raised over $2.6 billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2 billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.” moderna prospectus summary mRNA AZ = AstraZeneca (ICI, controlled by the Queen’s Golden Share) mrna chart https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220022435/xslF345X03/form4.xml MODERNA CEO STEPHANE BANCEL IS THE DICTIONARY DEFINITION OF AN INSIDE CORPORATE TRADER non derivatives securities 1 https://www.sec.gov/Archives/edgar/data/1443340/000112760220022138/xslF345X03/form4.xml non derivatives securities 2 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220022102/xslF345X03/form4.xml non derivatives securities 3 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220022102/xslF345X03/form4.xml non derivatives securities 4 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220021763/xslF345X03/form4.xml non derivatives securities 5 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220021495/xslF345X03/form4.xml non derivatives securities 6 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220021332/xslF345X03/form4.xml non derivative security 7 https://www.sec.gov/Archives/edgar/data/ 1443340/000089924320018777/xslF345X03/doc4.xml non derivatives securities 8 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220020892/xslF345X03/form4.xml non derivatives securities 9 https://www.sec.gov/Archives/edgar/data/ 1443340/000110465920079182/xslF345X03/a4.xml non derivatives securities 10 https://www.sec.gov/Archives/edgar/data/1443340/ 000112760220020206/xslF345X03/form4.xml non derivatives 11 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220019726/xslF345X03/form4.xml non derivatives 12 https://www.sec.gov/Archives/edgar/data/ 1443340/000112760220018531/xslF345X03/form4.xml non derivatives 13 The above screen captures are but a few of 120 SELLS from late 2019 to current See full list of Stephane Bancel Form 4 insider trading reports https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001443340 Here’s a full list of the Moderna Insiders https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852 moderna insiders moderna stock exchange See actual chart entries with hot links above moderna chart Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer https://www.fbcoverup.com/docs/ library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold- $31M-shares-SEC-FORM-4-Jul-29-2020.pdf http://www.bbbiotechventures.com/en/bb-biotech-ventures/ bb biotech Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Siemens, Hoffman-Roche, Harvard, . Executives Stéphane Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr. Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies. Juan Andres joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from 10 TABLE OF CONTENTS 2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain. Marcello Damiani joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr. Damiani held senior roles at bioMérieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr. Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France. Tracey Franklin has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms. Franklin held positions of increasing responsibility at Merck & Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University. Lori Henderson, J.D., has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms. Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms. Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College. Stephen Hoge, M.D., joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College. Lorence Kim, M.D., has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as a Managing Director and co-head of biotechnology investment banking. Dr. Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine. Tal Zaks, M.D., Ph.D., has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania. 11 TABLE OF CONTENTS Non-executive directors Noubar B. Afeyan, Ph.D., is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors. Stephen Berenson has served as a member of our board of directors since October 2017. Mr. Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr. Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from MIT. We believe that Mr. Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries. Robert Langer, Sc.D., has served as a member of our board of directors since December 2010. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr. Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors. Elizabeth Nabel, M.D., has served as a member of our board of directors since December 2015. Dr. Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, since 2010. Dr. Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr. Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr. Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations. François Nader, M.D., has served as a member of our board of directors since December 2019. Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail 12 TABLE OF CONTENTS Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr. Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors. Israel Ruiz has served as a member of our board of directors since February 2017. Mr. Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr. Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr. Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT’s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr. Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master’s degree from the MIT Sloan School of Management. We believe that Mr. Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT. Paul Sagan has served as a member of our board of directors since June 2018. Mr. Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr. Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr. Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr. Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr. Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields. Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions. Director nominee Sandra Horning, M.D., is nominated to serve as a Class II director on our board. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 13 TABLE OF CONTENTS 2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr. Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience. . . . . . . . This financial disclosure is from Moderna’s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018. It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic… Gates Foundation, DARPA, BARDA, Merck, AstraZeneca (ICI, British government, Queen’s Golden Share) and Moderna’s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust, agent of the Pilgrims Society and the Queen’s Privy Council) https://www.sec.gov/Archives/edgar/data/ 1682852/000119312518323562/d577473ds1.htm WHERE IS THE DEPARTMENT OF JUSTICE, SPECIFICALLY BILL BARR, ON BUSTING UP THIS INSIDER TRADING GROUP THAT IS TRYING TO EXTERMINATE HUMANITY, WHILE PROFITING A FEW BUCKS? bill barr bagpipes Postscripts: Douglas, You were so right. Moderna’s intitial public offering documents disloses MONCEF SLAOUI, PHD. as a director. He also shows your NIH suspicions true https://www.fbcoverup.com/docs/library/2018-12-04-Moderna-Inc-MRNA-CIK-0001682852-S-1A-Initial-Public-Offering-SEC-Edgar-Filed-Dec-04-2018.pdf#page=307 Moncef had been with GlaxoSmithKline (Wellcome Fund) since 1988. He then led worldwide business development then led Glaxo/Wellcome’s R&D in 2006. He then led the Oncology Business from 2010. GSK/Wellcome Fund jointly own Moncef’s company Galvani Bioelectronics, launched in 2016, with Verily Life Sciences. Verily Life Sciences is the new name of what was Google Life Sciences(renamed in 2015). https://en.wikipedia.org/wiki/Verily Enter warmonger Eric Schmidt directly into the Board of Moderna through the back door. Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions. MM ___ https://aim4truth.org/2020/08/04/modernas-totally- disqualifying-red-flag-strategic-relationships-to-the- queen-wellcome-trust-and-bill-gates/ xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx JAMES W. BREYER, FACEBOOK KINGPIN, IS THE BRITISH PILGRIMS SOCIETY SURROGATE IN CHINA AND LITERALLY XI JINPING’S RIGHT HAND MANCONTRIBUTING WRITERS | OPINION | AMERICANS FOR INNOVATION | DEC. 18, 2020, UPDATED FEB. 25, 2021 | PDF | https://tinyurl.com/y9k9qsl7 AFI. (Dec. 18, 2020). James W. Breyer, Facebook kingpin, is the British Pilgrims Society surrogate in China and literally Xi Jinping’s right-hand man. Americans for Innovation. Fig. 1—James W. Breyer: Chairman, Accel Partners (Palo Alto CA); director, IDG-Accel China; chairman, Breyer Capital; former chairman, National Venture Capital Association (2004-05, NVCA); Xi Jinping's right hand man for America's depopulation and destruction. Moderna's P-4 bioweapons lab in Indiana named Catalent producing the mRNA COVID DNA poison is controlled by British peers loyal to the Queen, Pilgrims Society, QintetiQ, C.I.A., MI6 and Wellcome Trust's Coronavirus Pirbright patent China is merely their dutiful front man. While DNC plotted coup against Trump in 2017, bank-tech traitors were in Beijing conspiring with Xi Jinping at Tsinghua University Elizabeth Frawley Bagley Fig. 2—Elizabeth Frawley Bagley. Attorney; DNC donor; former ambassador to Portugal (1994-97, Clinton); Global Partnerships Rep. (2009-10, Obama); Special Advisor to Hillary at State Department (2014-17); Portuguese Grand Cross. Dec. 18, 2020—On Oct. 31, 2017, while the DNC-British Crown Agents were plotting a coup against President Donald Trump at Elizabeth Bagley's Georgetown mansion, their banking and tech bag men were in Beijing arranging China’s cooperation in the takedown of the American Republic. Elizabeth Frawley Bagely is an attorney; DNC donor; former ambassador to Portugal (1994-97, Clinton); Global Partnerships Rep. (2009-10, Obama); Special Advisor to Hillary at State Department (2014-17); Portuguese Grand Cross. BRITISH, AMERICAN & CHINESE SPIES AND TRAITORS TO THE AMERICAN REPUBLIC James W. Breyer, Xi Jinping. (Oct. 31, 2017). Opening up of China means win-win cooperation for world: Premier Xi Jinping at Tsinghua Univerity, including James W. Breyer, IDG-Accel Partners China, Mark Zuckerberg, Facebook, Henry M. Paulson, Jr., Goldman Sachs, U.S. Treasury, Blackstone Group, Stephen Schwarzman, Tim Cook, Apple, David M. Rubenstein, Carlyle Group, John L. Thornton, Barrick Gold Corp, Satya Nadella, Microsoft, PDF, p. 15. China People's Daily. Fig. 3—James W. Breyer, Xi Jinping. (Oct. 31, 2017). Opening up of China means win-win cooperation for world: Premier Xi Jinping at Tsinghua Univerity, including James W. Breyer, IDG-Accel Partners China, Mark Zuckerberg, Facebook, Henry M. Paulson, Jr., Goldman Sachs, U.S. Treasury, Blackstone Group, Stephen Schwarzman, Tim Cook, Apple, David M. Rubenstein, Carlyle Group, John L. Thornton, Barrick Gold Corp, Satya Nadella, Microsoft, PDF, p. 15. China People's Daily. Source: China People's Daily. Reproduced for educational purposes only. Fair Use relied upon. Mark Elliot Zuckerberg Fig. 4—Mark Elliot Zuckerberg. Traitor to America. Other traitors at the Xi Jinping meeting were James W. Breyer, IDG-Accel Partners China, Mark Zuckerberg, Facebook, Henry M. Paulson, Jr., Goldman Sachs, U.S. Treasury, Blackstone Group, Stephen Schwarzman, Tim Cook, Apple, John L. Thornton, Barrick Gold Corp, David M. Rubenstein, Carlyle Group, Satya Nadella, Microsoft and no-name squirrelly banker (see photo). Photo lineups are important pecking-order messages in China. On Xi’s right is Breyer (Facebook), and on his left Henry Paulson (Goldman Sachs, Treasury). James W. Breyer Fig. 5—James W. Breyer. Traitor to America. British Pilgrims Society; China handler for the Pilgrims Society.In short, James W. Breyer, the former chairman of the National Venture Capital Association (NVCA), has sold out America to the British and their Chinese minions.Note: Stephen Schwarzman, Blackstone group chairman, even copied Cecil Rhodes’ Pilgrims Society scholarships. Blackstone/BlackRock is the third largest investor in Catalent, an mRNA COVID-19 vaccine P-4 laboratory producer in Bloomington, Indiana for Moderna, that Dr. Francis Boyle says is a bioweapon against your DNA in violation of the Nuremberg Code. Catalent boasted that they will produce 200 million doses of the poison by May 2021. Vice President Mike Pence visited Catalent on Tuesday, Dec. 15, 2020 and sang their praises, dubiously. Mark Elliot Zuckerberg Fig. 6—[Sir, CBE] Richard Gillingwater. British Pilgrims Society spy; director, Wellcome Trust (UK); chairman, Janus Henderson Group plc, 2nd largest investor in Catalent vaccine producer of the mRNA COVID-19 bioweapon for Moderna. The second largest investor in Catalent is the British company Janus Henderson Group plc whose chairman is (Sir [OBE] Richard Gillingwater) a current director of Wellcome Trust, partnered with the Gates Foundation in The Pirbright Institute (UK) who holds the patent on Coronavirus. Sir [OBE] Richard Gillingwater was an early director in British QintetiQ that has over $8 billion in U.S. contracts with the Navy and Space Wars and is controlled by the Queen’s Golden Share. Carlyle Group was QintetiQ's first investor. Former C.I.A. Director George Tenet was an early director followed by the former vice chairman of the Joint Chiefs Staff—Admiral Edmund P. Giambastiani Jr. Lord Mark Malloch-Brown Fig. 7—Lord Mark Malloch-Brown. British Pilgrims Society spy; Chairman, Smartmatic Voting election fraud Machine; co-founder Open Society Foundation (George Soros); U.N. Deputy Secretary General; director, Investec. See Lord Mark Malloch-Brown Biography and Timeline. Lord Mark Malloch-Brown controls Smartmatic that is attempting to perfect the greatest election fraud in history. Sir Nicholas Clegg, former British deputy prime minister, is Facebook’s global vice president of communications Baron Richard B. Allan is Facebook’s European vice president of communications. Allan's grandfather was British MI6 chief of staff responsible for formulating the treasonous "Five Eyes" agreement on Mar. 05, 1946. Bookmark: #fight-for-our-republic | https://tinyurl.com/y52oknth FRAUDULENT INDUCEMENT BY BREYER & ZUCKERBERG OF STANFORD STUDENTS IN 2005 TO BUILD ON STOLEN PROPERTY James W. Breyer, Mark E. Zuckerberg. (Oct. 26, 2005). Publicly and illegally solicit Stanford students to write social networking apps, inventions (stolen by the IBM Eclipse Foundation, but later U.S. Patents nonetheless) of Columbus OH inventor Leader Technologies and CEO Michael T. McKibben, MS&E 472, Entreprenuerial Thought Leaders Seminars, Prof. Kosmik et al. @ 49m 11secs. Stanford Center for Professional Development. Fig. 8—James W. Breyer, Mark E. Zuckerberg @49m11secs. (Oct. 26, 2005). Publicly and illegally solicit Stanford students to write social networking apps, inventions (stolen by the IBM Eclipse Foundation, but later U.S. Patents nonetheless) of Columbus OH inventor Leader Technologies, inventor and CEO Michael T. McKibben, MS&E 472, Entreprenuerial Thought Leaders Seminars, Prof. Tom Kosmik, Tom Byers, Tina Seelig. Stanford Center for Professional Development. https://youtu.be/WA_ma359Meg | (Raw *.mp4 video file) | TRANSCRIPT Listen to Breyer's shill in the Stanford audience. Watch their kiddiness. Watch Breyer squirm when he said he was not interested in an exit strategy. Listen carefully to Breyer's answer re. future media companies—classical Pilgrims Society position. Zuckerberg's nervous answers show his evident brain washing... "you know." See Crimeline, Oct. 26, 2005. MOVING THE "FACEBOOK ECOSYSTEM" TO CHINA WHILE: DEFRAUDING THE COURTS IN LEADER V. FACEBOOK & FLIPPING THE KEYS TO THE BRITISH PILGRIMS SOCIETY IN LONDON See also Kerry A. Dolan. (Nov. 03, 2011). Superstar Venture Capitalist Jim Breyer Is Super Bullish On China. Forbes. Porus P. Cooper. (May 09, 2005). James W. Breyer, NVCA, Accel Partners, Pilgrims Society: Venture capital turning global (to China), noting Carlyle Group, Kleiner Perkins etc. The Philadelphia Inquirer. ("'China will be the next Silicon Valley,' a worldwide hub of innovation.") QINETIQ HOLDINGS LIMITED, Co. No. 4586941. (Nov. 11, 2002). Certificate of Incorporation and related records. Companies House (UK). QinetiQ Holdings Limited, Co. No. 4586941 Annual Reports, 2002-2019. James W. Breyer, Yuri Milner. (Jan. 24-26, 2010). DLD10 - Spotlight (Jim Breyer, largest Facebook inside investor) and Yuri Milner, largest Facebook outside, Russian investor). DLDconference (Munich, Germany). "The U.S. venture business will decline. I think there are enormous opportunities globally, and that's where if I a coming out of school venture capitalist today, I would be on a plane to London [UK], Beijing [China] or Bangalore [India] and not necessarily Palo Alto, California... trying to build a plaform, an ecosystem around Facebook platform... 25% of our business will be from the U.S. and 75% from Europe, Israel, China and India... Mark Zuckerberg was an exceptional entrepreneur. (Interviewer David Kirkpatrick was the author of The Facebook Effect propaganda to promote the Mark Zuckerberg facebook origins fiction.) James W. Breyer. (Accessed Dec. 21, 2020). Director, Biography. Blackstone. Video: Stanford; For educational purposes only. Fair Use relied upon. Conclusion: COVID is a money-making hoax by the British Pilgrims Society bankers and their minions in the U.S. and China being used to take down President Trump and the American Republic. L/R: James P. Breyer, Facebook, IDG-Accel Partners China; Xi Jinping, China dictator; Henry M. Paulson, Goldman Sachs, Bush Treasury. Oct. 31, 2017. Fig. 9—TRAITORS: L/R: James P. Breyer, Facebook, IDG-Accel Partners China; Xi Jinping, China dictator; Henry M. Paulson, Goldman Sachs, Bush Treasury. Oct. 31, 2017. See James W. Breyer, Xi Jinping. (Oct. 31, 2017). Opening up of China means win-win cooperation for world:President Xi at Tsinghua U. incl. Zuckerberg, Paulson, Blackstone, Scwarzmann, Cook. China People's Daily. Request to President Trump: American patriots are with you, praying for you, your loyal staff and your family, and we urge you to insist that ballot signatures be verified one to one, no excuses, no passes for human error, etc. No matched signature, no vote counted for that ballot. Then, if necessary, martial law. (See 18 U.S. Code § 2381. Treason and 10 U.S. Code § 894 - Art. 94. Mutiny or sedition.) |
� 2018 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. We are not responsible for content written by and hosted on third-party websites. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. We assume no responsibility for the use or misuse of this material. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners. .......Tags: "israel nuked wtc" 9-11 Truth jfk assassination "cultural marxism" "holocaust hoax" "fake news" "fake history" fed censorship "mind control" tavistock holohoax auschwitz deep state kabbalah talmud bush obama clinton trump russiagate spygate israel britain saudi arabia middle east rothschild cold war comey brennan clapper yellow vests populism nuclear demolition communism marxism socialism pedophiliacontact: info@newsfollowup.com